ArticlePloS one2025
Trends and outcomes of cardiac arrest and extracorporeal membrane oxygenation during the COVID-19 pandemic in the United States.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 Pandemic challenged the healthcare system worldwide, but its effect on outcomes of cardiac arrest (CA) and extracorporeal membrane oxygenation (ECMO) use are understudied. We examined trends in CA, ECMO use and survival, and evaluated the impact of receiving care during the COVID-19 Pandemic on outcomes following CA. We also evaluated the impact of COVID-19 infection on outcomes following CA.
methodsAdults with out-of-hospital (OHCA) or in-hospital cardiac arrest (IHCA) were identified in the 2016-2020 National Inpatient Sample. For primary analysis, CA patients without COVID-19 were divided into Pre-Pandemic and Pandemic time-periods. For secondary analysis, CA patients treated during the Pandemic time-period were divided by COVID-19 infection status. Generalized linear models were used to evaluate associations between Pandemic time-period or COVID-19 infection with in-hospital mortality.
resultsOf 1,320,020 non-COVID-19 CA patients, 19.1% were managed during the Pandemic. From 2016-2019, CA incidence increased from 696 to 771 per 100,000 hospitalizations, and disproportionately increased to 1,023 per 100,000 hospitalizations by the end of 2020. Mortality for IHCA was stable prior to the Pandemic, but increased from 67.4% to 75.4% by the end of 2020, while mortality for OHCA was stable. ECMO use increased from 2016 to 2019 for OHCA and IHCA, declined during the second quarter of 2020, and recovered to pre-Pandemic levels by the end of 2020. After risk-adjustment, care during the Pandemic was associated with 1.2-fold greater odds of mortality after CA for non-COVID-19 patients. Among 277,975 patients experiencing CA during the Pandemic, 19.6% had concomitant COVID-19 infection. After risk-adjustment, COVID-19 infection was associated with 3.9-fold greater odds of mortality after CA.
conclusionCA incidence and mortality increased during the COVID-19 Pandemic, while ECMO use declined, emphasizing the need to improve care of CA and ECMO patients. COVID-19 patients with CA had dismal outcomes, suggesting no role for ECMO in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.